Marco L. Davila, Ph.D.
Affiliations: | 2004 | Duke University, Durham, NC |
Area:
ImmunologyGoogle:
"Marco Davila"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Garnett Kelsoe | grad student | 2004 | Duke | |
| (Cryptic RS function in mouse B-cell development.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Faramand RG, Lee SB, Jain MD, et al. (2024) Baseline serum inflammatory proteins predict poor CAR T outcomes in diffuse large B-cell lymphoma. Blood Cancer Discovery |
| Rejeski K, Perez A, Iacoboni G, et al. (2023) Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Science Advances. 9: eadg3919 |
| Lee DH, Chandrasekhar S, Jain MD, et al. (2023) Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study. Cardio-Oncology (London, England). 9: 18 |
| Stein-Thoeringer CK, Saini NY, Zamir E, et al. (2023) A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nature Medicine |
| Dong N, Lopes-Garcia LR, Viñal D, et al. (2023) Outcomes of CD19-directed Chimeric Antigen Receptor T-cell Therapy for Transformed Non-follicular Lymphoma. Transplantation and Cellular Therapy |
| Sallman DA, Kerre T, Havelange V, et al. (2023) CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. The Lancet. Haematology. 10: e191-e202 |
| Davila ML, Brentjens RJ. (2022) CAR T cell therapy: looking back and looking forward. Nature Cancer. 3: 1418-1419 |
| Fahrmann JF, Saini NY, Chia-Chi C, et al. (2022) A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. Cell Reports. Medicine. 3: 100720 |
| Boucher JC, Yu B, Li G, et al. (2022) Large Scale Ex Vivo Expansion of γδ T cells Using Artificial Antigen-presenting Cells. Journal of Immunotherapy (Hagerstown, Md. : 1997) |
| Wood AC, Perez AP, Arciola B, et al. (2022) Outcomes of CD19 targeted CAR T-cell Therapy for Patients with Reduced Renal Function Including Dialysis. Transplantation and Cellular Therapy |